Abstract: This invention relates to methods to prepare and compositions pertaining to branched ethylene-propylene copolymers that include at least 50% ethylene content by weight as determined by FTIR; a g?vis of less than 0.95; a Mw of 125,000 to 300,000; a methylene sequence length of 6 or greater as determined by 13C NMR, wherein the percentage of sequences of the length of 6 or greater is more than 32%; and can have greater than 50% vinyl chain end functionality.

Abstract: This invention relates to methods to prepare and compositions pertaining to branched ethylene-propylene copolymers that include at least 50% ethylene content by weight as determined by FTIR; a g?vis of less than 0.95; a Mw of 125,000 to 300,000; a methylene sequence length of 6 or greater as determined by 13C NMR, wherein the percentage of sequences of the length of 6 or greater is more than 32%; and can have greater than 50% vinyl chain end functionality.

Abstract: This invention relates to a copolymer prepared using two or more non-coordinating anion activators comprising a first C2 to C12 alpha olefin (such as ethylene), a second C3 to C12 alpha olefin (such as propylene) different from the first alpha olefin, and diene (such as ethylidene norbornene and/or vinyl norbornene), where the polymer has: a) first alpha olefin (ethylene) content of 35 to 90 mol %; b) second alpha olefin (propylene) content of 9.8 to 64.8 mol %; c) diene content of 0.2 to 5 mol %; d) a branching index g?ave of 0.95 or more; e) a complex viscosity ratio (eta*(0.01 rad/s)/eta*(100 rad/s), at 125° C.) greater than 1.

Abstract: This invention relates to a copolymer prepared using two or more non-coordinating anion activators comprising a first C2 to C12 alpha olefin (such as ethylene), a second C3 to C12 alpha olefin (such as propylene) different from the first alpha olefin, and diene (such as ethylidene norbornene and/or vinyl norbornene), where the polymer has: a) first alpha olefin (ethylene) content of 35 to 90 mol %; b) second alpha olefin (propylene) content of 9.8 to 64.8 mol %; c) diene content of 0.2 to 5 mol %; d) a branching index g?ave of 0.95 or more; e) a complex viscosity ratio (eta*(0.01 rad/s)/eta*(100 rad/s), at 125° C.) greater than 1.

Abstract: The present invention relates to the use of the Insulin-like growth factor-I (IGF-1) in immune modulation and/or in the treatment or prevention of pathogenic or aberrant immune responses or disorders and/or for use in the treatment or prevention of T-cell mediated disorders or diseases and/or for use in the treatment or prevention of diseases where the immune system contributes to the disease state.